» Articles » PMID: 20171681

Histological Subtype is an Independent Predictor of Outcome for Patients with Renal Cell Carcinoma

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2010 Feb 23
PMID 20171681
Citations 201
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: There are significant differences in clinicopathological features among renal cell carcinoma histological subtypes but controversy exists regarding the independent impact of histological subtype on patient outcome after nephrectomy. We examined the significance of histological subtype on progression to distant metastasis and cancer specific death after nephrectomy.

Materials And Methods: In a retrospective review of our institutional nephrectomy registry we identified 3,062 patients treated surgically for clear cell, papillary or chromophobe renal cell carcinoma between 1970 and 2003.

Results: We identified 2,466 patients (80.5%) with clear cell, 438 (14.3%) with papillary and 158 (5.2%) with chromophobe renal cell carcinoma. There were significant differences in age at surgery, gender, symptoms at presentation, tumor size, stage and grade, tumor necrosis, sarcomatoid differentiation and multifocality among the 3 renal cell carcinoma subtypes (p <0.01 for all). A significant difference in metastasis-free and cancer specific survival existed between patients with clear cell renal cell carcinoma and the 2 other subtypes, although no significant difference in these outcomes was identified between patients with the papillary and chromophobe subtypes. The clear cell renal cell carcinoma subtype remained a significant predictor of metastasis (HR 2.76, 95% CI 2.05-3.73) and cancer specific death (HR 1.77, 95% CI 1.38-2.26, each p <0.001) after multivariate adjustment for the features listed above.

Conclusions: Histological subtype is an independent predictor of progression to distant metastasis and cancer specific death in patients with renal cell carcinoma.

Citing Articles

The feedback loop between miR-222-3p and ZEB1 harnesses metastasis in renal cell carcinoma.

Wang F, Li L, Sun X, Cai X, Wang J, Luo H Cell Death Discov. 2025; 11(1):97.

PMID: 40074730 PMC: 11903659. DOI: 10.1038/s41420-025-02385-0.


A Novel Nomogram for the Prediction and Evaluation of Prognosis in Patients with Early-onset Kidney Cancer: a Population-based Study.

Lv D, Wang Q, Sun K, Li J, Zhou H, Wen J J Cancer. 2025; 16(4):1189-1201.

PMID: 39895778 PMC: 11786041. DOI: 10.7150/jca.104569.


Spatial and single-cell transcriptomics reveal cellular heterogeneity and a novel cancer-promoting Treg cell subset in human clear-cell renal cell carcinoma.

Song X, Zhu Y, Geng W, Jiao J, Liu H, Chen R J Immunother Cancer. 2025; 13(1).

PMID: 39755578 PMC: 11748785. DOI: 10.1136/jitc-2024-010183.


Discovering the interactome, functions, and clinical relevance of enhancer RNAs in kidney renal clear cell carcinoma.

Sun Z, Du H, Zheng X, Zhang H, Hu H BMC Med Genomics. 2025; 18(1):3.

PMID: 39754187 PMC: 11697625. DOI: 10.1186/s12920-024-02081-5.


Long-term effects of neoadjuvant chemotherapy in variant histology locally advanced colon cancer: a propensity score-matched analysis.

Wang Q, Jin S, Wang Z, Ju Y, Wang K Cancer Biol Ther. 2024; 26(1):2441511.

PMID: 39717890 PMC: 11702939. DOI: 10.1080/15384047.2024.2441511.